Citations

Clear

10 citation(s) found for "Shin, Ho Jin".

frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Lenz, Georg, Trněný, Marek, Burke, John M., Nowakowski, Grzegorz S., Düll, Johannes, Jeon, Youngwoo , Cheah, Chan, Westin, Jason, Ye, Joseph Z., Caguioa, Priscilla B. , Belada, David, Shin, Ho Jin, Amorim, Sandy, Colucci, Philomena, Ioannidis, Sonia, Lenz, Georg , Trněný, Marek , Burke, John M. , Nowakowski, Grzegorz S. , Fox, Christopher P. , Chiappella, Annalisa , Westin, Jason R. , Belada, David , Oh, Sung Yong , Colucci, Philomena M., Cheng, Lulu L , Vitolo, Umberto

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba7000 Get It

LBA7000 Background: ~40% of DLBCL pts are not cured with first-line (1L) R-CHOP, underscoring a significant unmet need for more effective 1L regimens. Tafa (anti-CD19 mAb) + Len-R-CHOP in the phase 1b First-MIND study demonstrated safety and efficacy in pts with newly diagnosed disease. frontMIND, a phase 3, double-blind, placebo-controlled study, compared Tafa-Len-R-CHOP vs R-CHOP in pts with high-risk aggressive BCLs. Methods: Pts aged 18–80 y with newly diagnosed, high-intermediate/high-risk DLBCL or HGBL (IPI 3–5, aaIPI 2–3 if ≤60 y) and ECOG PS 0–2 were randomized 1:1 to Tafa-Len-R-CHOP or R-CHOP. Primary endpoint was investigator-assessed PFS; secondary endpoints included: EFS, OS, CR, ORR, safety. Results: At primary analysis (data cutoff Oct 20, 2025), 899 pts were randomized to Tafa-Len-R-CHOP (n=448) or R-CHOP (n=451); baseline characteristics were similar between arms. With a median follow-up of 35.2 mo, Tafa-Len-R-CHOP achieved a statistically significant improvement in PFS vs R-CHOP (HR 0.75 [95% CI: 0.59, 0.96]; P =0.019) in the overall population; in pts with centrally confirmed lymphoma subtypes (n=773), PFS HR was 0.68 (95% CI: 0.52, 0.88) and 24-mo PFS was 72.7% vs 62.2%. PFS benefit was observed with Tafa-Len-R-CHOP in both molecular COO subtypes, ABC and GCB (data will be presented). Tafa-Len-R-CHOP significantly improved EFS vs R-CHOP; CR and ORR were similar between arms and HR for OS was 0.85 (final OS planned at 5y) (Table). Any-grade TEAEs were similar in treatment arms (98.6% vs 97.1%); more grade ≥3 TEAEs occurred with Tafa-Len-R-CHOP vs R-CHOP (86.7% vs 76.1%). Discontinuations due to TEAEs occurred in 25.7% vs 17.9% and deaths due to TEAEs in 5.9% vs 3.8% of pts for Tafa-Len-R-CHOP vs R-CHOP. Overall, there were fewer deaths with Tafa-Len-R-CHOP vs R-CHOP (18.5% vs 21.7%). Conclusions: The primary endpoint of frontMIND was met; Tafa-Len-R-CHOP resulted in a significant 25% reduction in risk of disease progression or death compared with R-CHOP, with an 8.2% difference in 24-month PFS rate in the overall population and 10.5% difference in pts with centrally confirmed lymphoma subtypes. TEAEs were manageable and consistent with the expected safety profile. Tafa-Len-R-CHOP represents a potential new 1L standard of care for pts with both COO subtypes of high-risk DLBCL or HGBL. Clinical trial information: NCT04824092 . Efficacy outcomes by treatment arm.* Variable Tafa-Len-R-CHOP(n=448) R-CHOP(n=451) HR or OR(95% CI) P value PFS, # events (%) † 121 (27.0) 155 (34.4) 0.75 (0.59, 0.96) 0.019 PFS rate at 24 mo, % 71.1 62.9 − − PFS rate at 36 mo, % 67.3 60.7 − − EFS, # events (%) 154 (34.4) 191 (42.4) 0.79 (0.64, 0.97) 0.026 OS, # events (%) 82 (18.3) 95 (21.1) 0.85 (0.63, 1.14) 0.270 CR at EOT, n (%) 292 (65.2) 294 (65.2) 0.998 (0.76, 1.31) 0.987 ‡ ORR at EOT, n (%) 360 (80.4) 343 (76.1) 1.290 (0.94, 1.78) 0.120 ‡ *Investigator-assessed. † Progressive disease or death from any cause. ‡ Nominal P value.
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Wixner, Jonas , Polydefkis, Michael , Ueda, Mitsuharu , Bender, Shaun, Jay, Patrick Y. , Yureneva, Elena, group, patisiran Global OLE study, Vita, Giuseppe, Rizzo, Vincenzo , Wiesman, Janice F. , Lau, Vincent , DeLong, Douglas, May, John J., Delmont, Émilien , Pouget, Jean, Grapperon, Aude‐Marie , Campana-Salort, Emmanuelle, Coutinho, Conceição de Azevedo, Campos, Catarina Falcão de , Coelho, Teresa , Reis, Antonio Hipólito, Pérez, Javier Martínez , Silva, Ana Martins da, Alves, Cristina , Cardoso, Márcio , Valdrez, Kátia, Monte, Julia R, Novais, Marta , Guimarães, Nádia, Cardoso, Inês , Freitas, Mónica, Ferreira, Natália , Kuzume, Daisuke , Morimoto, Yuko, Gauvain, Clément , Migaud-Chervy, Maria-Claire, Deplanque, Dominique , Jozefowicz, Elsa, Théaudin-Saliou, Marie, Cauquil-Michon, Cécile, Labeyrie, Céline , Not, Adeline , Lecoq, Anne-Lise , Stephant, Maeva, Echaniz‐Laguna, Andoni , Becquemont, Laurent , Beaudonnet, Guillemette , Eliahou, Ludivine , Slama, Michel , Signaté, Aïssatou , Darche, Paola, Grimaud, Jérôme, Berthelot, Emeline, Inamo, Jocelyn , Gendre, Thierry , Arrouasse, Raphaele , Ernande, Laura , Salhi, Hayet, Choumert, Ariane , Charlin, Cyril, Megelin, Thomas, Brannagan, Thomas H., Tsang, Steven, Wajnsztajn, Fernanda, Shije, Jeffrey, Ulane, Christina, Kleyman, Inna , Weimer, Louis H., Cioroiu, Comana , Kleopa, Kleopas A. , Zamba‐Papanicolaou, Eleni , Tada, Satoshi , Nagai, Masahiro , Ando, Rina, Yamanishi, Yuki , Overcash, J. Scott , Green, Sinikka, Coskun, Derya J, Manos, Paul S. , Zepeda, Karla A, O’Riordan, William, Cortese, Andrea , Bernardo, Daniela, Paolantonio, Andrea Di , Guglielmino, Valeria , Kristen, Arnt V. , Nagel, Christian , Siepen, Fabian aus dem , Hein, Selina , Campistol, Josep M. , Marín, Lida María Rodas, Pelicano, Josep Miquel Blasco, Dávila, Lucía Galán, Cordoba, Vanesa Pytel, Sola, A. Guerrero, Feijoo, Julián García, Isla, Leopoldo Pérez de , Moreira, Carolina Lavigne , Marques, Vanessa Daccach , Beamud, Francisco Muñoz, Borrachero, Cristina, Sanz, Mónica, Oliver, E, Moreno, Juan González, Martinez, J. Michael, Descals, Cristina, Usón, Mercedes, Vega, Francisco Jose, Figuerola, Antoni, Montalà, Carles, Abreu, Aline França de , Silva, Moises Dias da, Rosa, Renata Gervais de Santa, Berensztejn, Amanda Cardoso, Guedes, Mariana de Andrade, Lautre, Andrea, Orellana, Lucas, Briseño, Maria Alejandra González-Duarte, Parra, David Rivera de la, Reyes, Jose Pablo Hernandez, Alba, Maria del Mar Saniger, Parman, Yeşim , Serbest, Nail Güven , Durmuş, Hacer , Karamürsel, Saçit , Elitok, Ali, Inan, Nermin G Sirin, Altinkurt, Emre, Polydefkis, Michael, Allen, Adriane C, Chaudhry, Vinay , Jarrett, R. J., Bressler, Neil M. , Khoshnoodi, Mohammad , Lui, Alvin T, Chung, Tae , Vista, Geno, Shah, Syed Mahmood , Hamaguchi, Hirotoshi , Oda, Tetsuya , Shimomura, Masahiro, Kim, Hee Jin, Misumi, Yohei , Nomura, Toshiya , Tateishi, Takahisa , Mauricio, Elizabeth A. , Dimberg, Elliot L., Fonder, Amie , Hobbs, Miriam, Dyck, P. James B. , Leung, Nelson , Hwa, Yi L. , Kapoor, Prashant , Kumar, Shaji , Dingli, David , Gove, Linde E., Dalia, Samir , Croy, David, Holding, Tim, Gorevic, Peter D., Su, Jen-Jen , Lin, Chao-Wen, Ajroud‐Driss, Senda , Sufit, Robert , Li, John-Michael, Freimer, Miriam , LoRusso, Samantha, Aso, Yasuhiro , Kim, Byoung‐Joon , Kim, JuHyeon, Jeon, Eun‐Seok , Seok, Jin Myoung , Park, Jae Hong , Sekijima, Yoshiki , Kato, Naga-aki, Hineno, Akiyo , Kodaira, Minori , Yoshinaga, Tsuneaki , Takasone, Ken, Miyahara, Teruyoshi, Takahashi, Yusuke , Matsumoto, Kazuhiko , Lin, Kon-Ping, Lee, Yi‐Chung , Wixner, Jonas, Pilebro, Björn, Nordh, Erik, Chermenina, Maria, Nygren, Anneli, Tournev, Ivaylo, Zhelyazkova, Sashka , Cherneva, Zheyna , Sarafov, S., Cherninkova-Gopina, Sylvia, Vorona, Elena, Huesing-Kabar, Anna, Schilling, Matthias , Kabar, Iyad , Martinez–Naharro, Ana , Chacko, Liza , Cohen, Oliver , Law, Steven , Rezk, Tamer , Quan, Dianna , Dixon, Stacy, Fridman, Vera , Low, Soon-Chai , Mezei, Michelle M. , Jack, Kristin, Wade, N. Kevin, Lopate, Glenn, Geisler, Stephanie , Sommerville, R. Brian, Florence, Julaine, Stewart, Graeme J., Taylor, Mark , Suan, Daniel, Dingli, David , Gillmore, Julian D , Lee, Yi-Chung , Karamursel, Sacit , Adams, David , Berk, John L. , Conceição, Isabel , Dispenzieri, Angela , Peltier, Amanda , Bender, Shaun , Capocelli, Kelley, Obici, Laura , group, patisiran Global OLE study, Vita, Giuseppe, Russo, Massimo , Mazzeo, Anna Teresa , Gentile, Luca, Kaku, Michelle C. , Lau, Vincent, Dalton, James, May, John, Attarian, Shahram , Verschueren, Annie , Campana-Salort, Emmanuelle, Neves, Carlos, Santos, Miguel Oliveira , Coelho, Teresa, Correia, Nuno, Perez, Javier M, Silva, Ana Martins da, Ramalho, Joana, Yamasaki, Masahiro , Morimoto, Yuko, Tard, Céline , Hachulla, É. , Lebellec, Loïc , Théaudin, Marie , Al‐Salameh, Abdallah , Algalarrondo, Vincent , Rousseau, Antoine , Planté‐Bordeneuve, Violaine , Ayache, Samar S. , Corvoisier, Philippe Le , Waters, Michael, Manos, Paul, Lozza, Alessandro , Merlini, Giampaolo , Rosti, Vittorio , Sabatelli, Mario , Bisogni, Giulia , Luigetti, Marco , Romano, Ângela , Nienhuis, Hans L. A. , Neshige, Shuichiro , Horga, Alejandro , Feijoo, Julián García, Marques, Wilson , López, Inés AL, Sanz, Monica, Martinez, Jose M Gamez, Waddington‐Cruz, Márcia , Abreu, Aline Souza de, Silva, Moises Dias da, Pinto, Marcus Vinícius , Pinto, Luiz Felipe , Barroso, Fábio , Briseno, Maria Alejandra Gonzalez Duarte, Cárdenas‐Soto, Karla , Cantú-Brito, Carlos Gerardo , Şahin, Erdi , Çakar, Arman , İNAN, NERMİN GÖRKEM ŞİRİN, Polydefkis, Michael, Jarrett, Raquel, Singh, Mandeep , Judge, Daniel P. , Lui, Alvin T, Vista, Geno, Shimomura, Masahiro, Scheid, Christof , Holtick, Udo , Oh, Jeeyoung , Kim, Hee Jin, Shin, Hyun Jin , Choi, Kyomin , Mauricio, Elizabeth A. , Cooper, Leslie T. , Gonsalves, Wilson I. , Witzig, Thomas E. , Lin, Yi , Rajkumar, S. Vincent , Gertz, Morie A. , Chao, Chi‐Chao , Lee, Ming‐Jen , Hsieh, Sung‐Tsang , Tsai, Li‐Kai , Yeh, Shin‐Joe , Yang, Chih‐Chao , Lee, Ga-Yeon , Cho, Eun Bin , Min, Ju‐Hong , Lee, Hye Lim , Kishida, Dai , Imai, Akira, Lin, Kon‐Ping, Wixner, Jonas, Suhr, Ole B. , Anan, Intissar , Nordh, Erik, Domellöf, Fátima Pedrosa , Chamova, Teodora , Schmidt, Hartmut , Tepasse, Phil‐Robin , Gillmore, Julian D. , Lachmann, Helen J. , Goh, Khean Jin , Geisler, Stephanie, Taylor, Mark, Suan, Dan

Mayo Clinic

JAMA Neurology | January 13, 2025 | Volume: 82 | Issue: 3 | Pages: 228

10.1001/jamaneurol.2024.4631 | PMID 39804640 Get It

Importance There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the longest-term data to date on patisiran for hATTR-PN. Objective To present the long-term efficacy and safety of patisiran in adults with hATTR-PN. Design, Setting, and Participants This global open-label extension (OLE) of the APOLLO randomized clinical trial and phase 2 OLE study enrolled patients from 43 hospitals or clinical centers across 19 countries between July 2015 and August 2017, with follow-up until November 2022. Of 212 eligible patients with hATTR who completed the phase 3 APOLLO or phase 2 OLE parent studies, 211 enrolled in and 138 completed the global OLE. Intervention Patisiran, 0.3 mg/kg, intravenously once every 3 weeks for up to 5 years. Main Outcomes and Measures Outcomes evaluated at year 5 of the global OLE included disability (polyneuropathy disability [PND] score); polyneuropathy severity (Neuropathy Impairment Score [NIS]), nutritional status (modified body mass index [mBMI]), quality of life (Norfolk Quality of Life–Diabetic Neuropathy [Norfolk QOL-DN]), and Rasch-Built Overall Disability Scale (R-ODS), with no statistical hierarchy. Safety, survival probability, and mortality were also assessed. Results At the global OLE baseline, the mean (SD) age was 61.3 (12.3) years, and 156 patients (73.9%) were male. In 138 patients completing the study, PND scores remained stable or improved in 89 patients (65.0%), NISs showed a mean (SD) change of 10.9 (14.7), and mean (SD) mBMI (calculated as weight in kilograms divided by height in meters squared times serum albumin in grams per liter) increased by 46.4 (120.7) over 5 years from baseline. Norfolk QOL-DN and R-ODS scores showed mean (SD) changes of 4.1 (16.7) and –3.7 (6.2), respectively. Adverse events (AEs) leading to study withdrawal occurred in 47 patients (22.3%). Infusion-related reactions were the most common treatment-related AE (n = 34 [16.1%]). Overall, 41 patients (19.4%) died during the study. Patisiran treatment in the parent study and low familial amyloid polyneuropathy score at parent study baseline were associated with significantly improved survival. Conclusions and Relevance In the longest study of an RNAi therapeutic for any disease, patisiran treatment resulted in modest changes for patients with hATTR-PN with an acceptable safety profile. These results highlight the importance of initiating early treatment for hATTR and the potential of RNAi therapeutics in medicine. Trial Registration ClinicalTrials.gov Identifier: NCT02510261
Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor
Chanan‐Khan, Asher , Lentzsch, Suzanne , Horvath, Noemi , Capra, Marcelo , Ovilla, Roberto, Jo, Jae‐Cheol , Shin, Ho‐Jin , Qi, Ming , Deraedt, William , Schecter, Jordan M. , Amin, Himal, Qin, Xiang , Casneuf, Tineke, Sasser, A. Kate, Sonneveld, Pieter , Quach, Hang , Chiu, Christopher

Mayo Clinic

Blood | October 11, 2019 | Volume: 128 | Issue: 22 | Pages: 3313-3313

10.1182/blood.v128.22.3313.3313 Get It

Abstract Introduction: Daratumumab is a human CD38 IgGκ monoclonal antibody that demonstrated significant activity and a manageable safety profile in combination with bortezomib and dexamethasone. In a randomized phase 3 study, daratumumab in combination with bortezomib and dexamethasone (DVd) significantly prolonged progression-free survival (PFS) versus bortezomib and dexamethasone alone (Vd) in a pre-specified interim analysis of patients (pts) with relapsed or refractory multiple myeloma (RRMM; Palumbo A. N Engl J Med 2016; in press). Herein, we examine subgroups from this study to compare the efficacy of DVd vs Vd in bortezomib-naive and bortezomib-experienced pt populations. In addition, the efficacy of DVd vs Vd in pts who were refractory to lenalidomide at last prior line of therapy was also evaluated. Methods: Pts who received ≥1 prior line of therapy were randomized (1:1) to 8 cycles (q3w) of Vd (bortezomib: 1.3 mg/m2 SC on Days 1, 4, 8, 11; dexamethasone: 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12) with or without daratumumab (16 mg/kg IV qw in Cycles 1-3, Day 1 of Cycles 4-8, then q4w until progression). Pts who were refractory to bortezomib were not eligible. The primary endpoint was PFS. Bone marrow aspirate samples that had been prepared with Ficoll were evaluated for minimal residual disease (MRD) using three different thresholds (10-4, 10-5, and 10-6) based on the ClonoSEQ assay (Adaptive Biotechnologies, Seattle, WA, USA). Results: Median follow-up was 7.4 months. Among bortezomib-naive pts (DVd, n=89; Vd, n=83), PFS was significantly improved with DVd vs Vd (median: not reached [NR] vs 7.5 months; HR, 0.25; 95% CI, 0.13-0.47; P<0.0001); estimated 12-month PFS rates were 72% vs 28%, respectively. ORR was 88% with DVd vs 70% with Vd (P=0.0040), with ≥very good partial response (VGPR) rates of 72% vs 42% (P<0.0001), and ≥complete response (CR) rates of 30% vs 20% (P=0.1199), respectively. For pts who previously received a bortezomib-containing regimen (DVd, n=162; Vd, n=164), PFS was also significantly longer with DVd vs Vd (median: 12.3 vs 6.7 months; HR, 0.46; 95% CI, 0.32-0.66; P<0.0001). Estimated 12-month PFS rates were 55% vs 27%, respectively. ORR was significantly higher with DVd vs Vd (80% vs 60%; P=0.0001), along with significantly higher rates of ≥VGPR (52% vs 22%; P<0.0001) and ≥CR (13% vs 3%; P=0.0019). Among pts who were refractory to lenalidomide at the last prior line of therapy (DVd, n=45; Vd, n=60), PFS was significantly longer in DVd vs Vd (median: 10.3 vs 4.4 mo; HR, 0.37; 95% CI, 0.21-0.65; P=0.0004; Figure). Within this subgroup, ORR was significantly higher for DVd vs Vd (81% vs 50%; P=0.0021), and the same trends were observed for rates of ≥VGPR (54% vs 12%; P<0.0001) and ≥CR (20% vs 5%; P=0.0261). Updated efficacy and safety data, including MRD analyses across different sensitivity thresholds (10-4, 10-5, and 10-6), will be presented at the meeting. Conclusions: These analyses confirm that addition of daratumumab to Vd significantly improves outcomes for RRMM pts regardless of prior treatment with bortezomib. Importantly, this treatment benefit of DVd vs Vd was maintained in pts who were refractory to lenalidomide at the last prior line of therapy. These data lend further support to adding daratumumab to a standard-of-care regimen in RRMM. Figure Progression-free Survival in Patients Refractory to Lenalidomide at the Last Prior Line of Therapy Figure. Progression-free Survival in Patients Refractory to Lenalidomide at the Last Prior Line of Therapy Disclosures Lentzsch: BMS: Consultancy; Foundation One: Consultancy; Celgene: Consultancy, Honoraria. Quach:Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Ovilla:Janssen: Consultancy. Qi:Janssen: Employment. Deraedt:Janssen: Employment, Equity Ownership. Schecter:Janssen: Employment, Equity Ownership. Amin:Janssen: Employment. Qin:Janssen: Employment. Casneuf:Johnson & Johnson: Equity Ownership; Janssen R&D, Beerse, Belgium: Employment. Chiu:Janssen: Employment. Sasser:Johnson & Johnson: Equity Ownership; Janssen Pharmaceuticals R&D: Employment. Sonneveld:Karyopharm: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding.
PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D‐VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK
Spencer, Andrew , Lentzsch, Suzanne , Spicka, I., Lauri, Birgitta, Lee, J.‐J., Nooka, A., Munder, Markus , Lee, C., Barreto, Wolney, Min, Chang‐Ki , Chanan‐Khan, A.A., Horvath, Noemi , Capra, Marcelo , Ovilla, Roberto, Jo, Jin-Hyeong, Shin, Ho‐Jin , Sonneveld, Pieter , Soong, David, Casneuf, Tineke, Ukropec, Jon, Qi, Ming , Mateos, M.‐V., Weisel, Katja C , Avet‐Loiseau, Hervé , Mark, Tomer M , Spicka, I., Masszi, Tamás , Levin, Mark-David , Bosi, Alberto , Hungria, Vânia , Cavo, Michèle , Quach, Hang , Corradini, Paolo , Beksaç, Meral , Chiu, C., Amin, H., Qi, M.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 251

10.1097/01.hs9.0000560672.85259.7d Get It

Background:Patients (pts) with multiple myeloma associated with high cytogenetic risk abnormalities have poor outcomes. In CASTOR, D‐Vd prolonged progression‐free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited a manageable safety profile in pts with RRMM. We conducted a subgroup analysis of D‐Vd vs Vd in CASTOR, based on cytogenetic risk.Aims:The purpose of this analysis was to determine the efficacy and safety of D‐Vd in CASTOR based on cytogenetic risk status.Methods:Eligible pts received ≥1 prior line of therapy. Cytogenetic risk was based on a combined analysis of next‐generation sequencing (NGS) and fluorescence in situ hybridization (FISH)/karyotype testing. High‐risk pts had t(4;14), t(14;16), or del17p abnormalities. Standard (std)‐risk pts were confirmed negative for all 3 abnormalities. Minimal residual disease (MRD; 10–5) was assessed via NGS using clonoSEQ® assay V2.0.Results:In CASTOR (D‐Vd, n = 251; Vd, n = 247), high‐risk was confirmed in 26.7% and 25.9% of pts in the D‐Vd and Vd groups, respectively. At a median follow up of 40.0 months (mo), D‐Vd prolonged PFS vs Vd in pts with high‐ (median 13.4 vs 7.2 mo; HR, 0.40 [95% CI, 0.24–0.65]; P = 0.0002) or std‐risk (median 18.4 vs 6.8 mo; HR, 0.28 [95% CI, 0.20–0.37]; P <0.0001). Higher ORR was seen with D‐Vd vs Vd (high risk: 84.8% vs 60.0%; P = 0.0226; std risk: 85.4% vs 65.0%; P <0.0001), including deep responses of ≥CR (high risk: 33.3% vs 8.3%; std risk: 29.9% vs 10.2%) and ≥VGPR (high risk: 65.2% vs 35.0%; P = 0.0049; std risk: 64.3% vs 28.0%; P <0.0001). Higher rates of MRD negativity (high risk: 17.9% vs 0%; P = 0.0003; std risk: 13.3% vs 2.4%; P = 0.0003), and sustained MRD negativity for ≥6 mo (high risk: 16.4% vs 0%; P = 0.0006; std risk: 6.1% vs 1.8%; P = 0.0859) and ≥12 mo (high risk: 7.5% vs 0%; P = 0.0581; std risk: 1.8% vs 0%; P = 0.2477) were seen with D‐Vd vs Vd. D‐Vd significantly prolonged PFS vs Vd in pts with one prior line of therapy only (high risk: median 20.1 vs 8.4 mo; HR, 0.30 [95% CI, 0.14–0.64]; P = 0.0012; std risk: median 32.6 vs 7.9 mo; HR, 0.18 [95% CI, 0.11–0.29]; P <0.0001; Figure). Additionally, D‐Vd significantly prolonged PFS2 (high risk: median 27.9 vs 18.6 mo; HR, 0.59 [95% CI, 0.37–0.94]; P = 0.0258; std risk: median 40.1 vs 21.6 mo; HR, 0.43 [95% CI, 0.32–0.59]; P <0.0001) regardless of cytogenetic risk status.Additional data including safety analyses will be presented.Summary/Conclusion:Adding daratumumab to Vd demonstrates significant efficacy in pts with high‐risk RRMM including PFS2. Among high‐risk RRMM pts, MRD negativity was only achieved with D‐Vd. These findings support use of D‐Vd for high‐risk RRMM. NCT02136134image
Usefulness of a Longitudinal Fixing Method with Two Bulldog Vascular Clamps for End-to-Side Anastomosis in Head and Neck Reconstruction
Shin, Jin Yong , Roh, Si‐Gyun , Chang, Suk Choo , Lee, Nae‐Ho

Mayo Clinic

Plastic & Reconstructive Surgery | February 28, 2019 | Volume: 143 | Issue: 3 | Pages: 675e-677e

10.1097/prs.0000000000005358 | PMID 30601317 Get It

Predictive Laboratory Findings of Lower Extremity Amputation in Diabetic Patients: Meta-analysis
Kim, Jong-Lim , Shin, Jin Yong , Roh, Si‐Gyun , Chang, Suk Choo , Lee, Nae‐Ho

Mayo Clinic

The International Journal of Lower Extremity Wounds | November 16, 2017 | Volume: 16 | Issue: 4 | Pages: 260-268

10.1177/1534734617737660 | PMID 29141468 Get It

Lower extremity amputation is a source of morbidity and mortality among diabetic patients. This meta-analysis aimed to identify significant laboratory data in patients with diabetic foot ulcer with high rates of lower extremity amputation. We performed a systematic literature review and meta-analysis using MEDLINE, EMBASE, and Cochrane databases. We extracted and evaluated 11 variables from the included studies based on amputation rates. This study used the Newcastle-Ottawa Scale to assess the quality of the studies. The search strategy identified 101 publications from which we selected 16 articles for review. We identified HbA1c, fasting blood glucose, white blood cells, C-reactive protein, and erythrocyte sedimentation rate as predictive variables of higher major amputation rate. Although further investigation of long-term and prospective studies is needed, we identified 5 variables as predisposing factors for higher major amputation in diabetic patients through meta-analysis.
Unusual Aspergillus Infection After Dermal Filler Injection
Shin, Jin Yong , An, Mun-Young, Roh, Si‐Gyun , Chang, Suk Choo , Lee, Nae‐Ho

Mayo Clinic

Journal of Craniofacial Surgery | September 29, 2017 | Volume: 28 | Issue: 8 | Pages: 2066-2067

10.1097/scs.0000000000004034 | PMID 28968322 Get It

Abstract According to a great desire for facial rejuvenation, dermal filler is promising for improving people's appearance without surgery. In a society of plastic surgery, injection of dermal filler is one of the most common procedures for a younger appearance. An increase in patients who have filler injection has been paralleled by a rise in various adverse reactions. Formation of inflammatory or infected nodules is one of the most common long-term complications. Infections can be increased because of improper disinfection of the patient's skin, a poor injection technique, decreased general immunity, and the presence of pathogens. The majority of bacteria are aerobic or facultative aerobic bacteria. This expectation of pathogens is critical for deciding on the antibiotic treatment before confirming the pathogen by microbial culture. The authors experienced unusual culture results in a patient with a chronic inflammatory nodule with abscess formation. The authors report a unique Aspergillus-cultured infection after filler injection.
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases
Blitterswijk, Marka van , Vlam, Lotte, Doormaal, Perry T.C. van , Seelen, Meinie, Medic, Jelena, Dooijes, Dennis , Visser, Marianne de, Kooi, Anneke J. van der , Raaphorst, Joost , Schelhaas, Helenius J. , Pol, W. Ludo van der , Veldink, Jan H. , Berg, Leonard H. van den , Aisen, Paul , Petersen, Ronald C., Clifford, R. Jack, Jagust, William, Trojanowki, John Q., Liu, Enchi , Montine, Tom, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Harvey, Danielle, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles, Bandy, Dan, Foster, Norm, Reiman, Eric M., Mathis, Chet, Cairns, Nigel J. , Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Foroud, Tatiana, Potkin, Steven, Kachaturian, Zaven, Frank, R.T., Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James B., Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald C. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Honig, Lawrence S., Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn , Onyike, Chiadi U. , Kielb, Stephanie , Glodzik, Lidia , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Arnold, Steven E. , Karlawish, Jason H., Smith, Charles D., Hardy, P. , Lopez, Oscar L., Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem, Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Bartzokis, George, Lu, Po H. , Apostolova, Liana G. , Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin, Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Black, Sandra, Caldwell, Curtis, Assaly, Michele, Kertesz, Andrew , Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Wu, Chuang‐Kuo, Johnson, Nancy E., Mesulam, Marsel, Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen A., Reynolds, Brigid, Sperling, Reisa A., Frey, Meghan , Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Belden, Christine M. , Jacobson, Sandra A. , Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Robert , Asthana, Sanjay , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J., Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Kwon, Sun-Uck, Kim, Joon‐Tae , Cho, Ki-Hyun , Ko, Y.J., Lee, Soo Joo , Cha, Jae-Kwan, Shin, Dong-Jin, Jang, Hyuk Jae, Choi, Nack‐Cheon , Hong, Seok-Chang, Rha, Joung-Ho, Kim, Eung‐Gyu , Choi, Jay Chol , Shin, Won Chul , HyukHeo, Sung, Chung, Kyung Cheon, Lee, Jun Hong , Bae, Hee‐Joon , Lee, Tae‐Kyeong , Jeong, Dushin, Lee, Jun , Ashwal, Steve, deVeber, Gabrielle , Ichord, Rebecca , Kirkham, Fenella J. , Lynch, John K., O’Callaghan, Finbar , Pavlakis, Steve, Sébire, Guillaume , Willan, Andrew R. , Dlamini, Noma, Nowak-Göttl, Ulrike, Düring, Christine, Plumb, Patricia , Journeycake, Janna M., Bruinhorst, Katrina van de, Gossett, Daniel R., Chavez, Marta Isabel Hernandez, Barnes, Chris , Furmedge, Janine, Gordon, Anne , Benedict, Susan, Bale, James F. , Nielson, Denise, Kabbouche, Marielle A., Karti, Pooja, Phillips, Tonya, Rizkallah, Élie, Zamel, Khaled, Wiznitzer, Max , Lidsky, Karen , Bernard, Timothy J. , Goldenberg, Neil A. , Booth, Frances, Nash, Monica, Beslow, Lauren A. , Carpenter, Jessica L. , Weinstein, Steven L., Li, Kan , Smith, Robin, Maytal, Joseph, Sy-Kho, Rosemarie, Yager, Jerome Y. , Massicotte, Patti, McClure, Chalmer, Hukin, Juliet, Bucevska, Marija, Kent, Sheila, Riviello, James J. , Rivkin, Michael, Trenor, Cameron C. , Whelan, Harry T. , Goodman, Sharon, Levinson, Kim, Kolk, Anneli , Laugesaar, Rael , Talvik, Tiina, Imam, Hussain, Thomas, Terrence , Kirton, Adam , Ganesan, Vijeya , Saengpattrachai, Montri, Crosswell, Hal E., Mancuso, Ann, Yeh, E. Ann , Humpherys, Peter, Abraham, Lisa , Alveal, Lucila Andrade, Ortiz, Manuel Arriaza, Altuna, Diana, Maxit, Clarisa, González, Verónica , Alam, Muhammad Rafiqul , Buckley, David , Penney, Sharon, Grabowski, Eríc F. , Deray, Marcel J., Khatib, Zaid, Kosofsky, Barry E. , Leifer, Dana , Nass, Ruth, Wong, Virginia, Catsman, Coriene E. , El-Hakam, Lisa Michael, Cholette, Jill M., Narang, Shalu, Lerner, Norma B., Carpenter, Shannon L. , Bischoff, Kurt, Frei‐Jones, Melissa , Masur, David, Gallentine, William B., Rende, Elizabeth K., Provenzale, James, Voyvodic, James , Song, Allen W. , Conklin, Terrie, O’Hara, Kathryn, Seinfeld, Syndi, Conry, Joan A. , Ayala, Jennifer , Facchini, Ronda, Sigalova, Maryana, Hannigan, James, Mancini, Ann , Curran, John S. , Ahlm, Sarah, Renaldi, J., Umanzour, Diana K, Kim, Andrew, Hamidullah, Aaliyah, Litherland, Claire , Bonner, Melanie, Xu, Yuan , Water, Virginia Van de, Grasso, Susan, Culbert, James, Bush, Brian J., Chandrasekaran, Sreedevi, Davis, Lori L. , Rogers, Christiane, Sabo, Cynthia , Wang, Helen H. , Lee, Ting‐Yim , Rheenen, Wouter van , Huisman, Mark H. B. , Weiner, Michael D. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C. , Donohue, Michael , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Koeppe, Robert A. , Reiman, Eric M. , Chen, Kewei , Mathis, Chet, Lee, Virginia M.‐Y. , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Clark, David , Grossman, Hillel, Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Karlawish, Jason , Wolk, David A. , Jicha, Gregory A. , Lopez, Oscar L., Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Farlow, Martin R. , Stefanovic, Bojana , Hsiung, Ging‐Yuek Robin , Feldman, Howard , Martínez, Walter Fabián , Turner, Raymond Scott , Sabbagh, Marwan Noel , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Fletcher, Evan M. , Carmichael, Owen , Johnson, Sterling C. , Carlsson, Cynthia M. , Potkin, Steven G. , Preda, Adrian , Nguyen, Dana R. , Scharre, Douglas W. , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Shin, Dong‐Ick , Kim, Yong‐Jae , Rha, Joung‐Ho , Hong, Keun‐Sik , Sohn, Sung‐Il , Park, Jong‐Ho , Park, Jong‐Moo , Park, Tai Hwan , Han, Moon‐Ku , Kwon, Hyung‐Min , Lee, Kyung‐Bok , Ashwal, Steven, Ferriero, Donna Marie , Fullerton, Heather J. , Lynch, John K., Sofronas, Marianne , Elbers, Jorina M. , Krümpel, Anne , Monagle, Paul , Mackay, Mark T. , Abdalla, Abdalla , Chadehumbe, Madeline , Friedman, Neil , Armstrong, Jennifer , Chang, Taeun , Sy-Kho, Rose Marrie, Björnson, Bruce , Hukin, Juliette , Amlie‐Lefond, Catherine , Fox, Christine K. , Golomb, Meredith R. , Heyer, Geoffrey L. , Tatishvili, Nana Nino , Jordan, Lori C. , Chan, Anthony K.C. , Kovacevic, Gordana S. , Epstein, Leon G. , Bagiella, Emilia , Hinton, Veronica J. , Voyvodic, James T., Glauser, Tracy A. , Weiss, Erica F , Kushner, David B. , BUSH, BRIAN J. , Noebels, Jeffrey L. , van Blitterswijk, Marka , Veldink, Jan H

Mayo Clinic

Neurology | July 27, 2012 | Volume: 79 | Issue: 9 | Pages: 878-882

10.1212/wnl.0b013e3182661d14 | PMID 22843265 Get It

Comparative diagnostic utility of1H MRS and DWI in evaluation of temporal lobe epilepsy
Kantarci, Kejal , Shin, Chul-Jin , So, E. L., Cascino, Gregory D. , Jack, Clifford R. , Britton, Jeffrey W. , Jack, Clifford R , Kantarci, Kejal

Mayo Clinic

Neurology | May 14, 2012 | Volume: 58 | Issue: 12 | Pages: 1745-1753

10.1212/wnl.58.12.1745 | PMID 12084871 Get It